Bicycle Therapeutics Limited

172 articles about Bicycle Therapeutics Limited

• Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer

  9/11/2023

  Bicycle Therapeutics today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FDA).

• Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

  9/5/2023

  Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET.

• Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/3/2023

  Bicycle Therapeutics Limited plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates.

• Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  7/18/2023

  Bicycle Therapeutics plc today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,648 American Depositary Shares (“ADSs”), each representing one ordinary share.

• Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

  7/13/2023

  Bicycle Therapeutics plc announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price to the public of $21.25 per share, for gross proceeds of approximately $200.0 million.

• Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

  7/12/2023

  Bicycle Therapeutics plc announced that it has commenced an underwritten public offering of $200 million of American Depositary Shares, each representing one ordinary share and, in lieu of ADSs to investors that so choose, non-voting ordinary shares.

• Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer

  6/23/2023

  Bicycle Therapeutics plc today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th.

• Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit

  6/13/2023

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on June 20th, 2023 at 12:30 p.m. ET.

• Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference - May 31, 2023

  5/31/2023

  Bicycle Therapeutics plc today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on June 7th, 2023 at 10:30 a.m. ET.

• Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

  5/11/2023

  Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results.

• Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology

  5/10/2023

  Bayer and Bicycle Therapeutics plc today announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets.

• Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

  5/4/2023

  Bicycle Therapeutics plc announced that it has entered into a collaboration with the German Cancer Research Center, to develop and discover Bicycle® radio conjugates for a range of oncology targets.

• Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.

• Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

  4/14/2023

  Bicycle Therapeutics plc today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.

• Bicycle Therapeutics Enhances Leadership Team with Key Appointments

  4/3/2023

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31.

• 

  Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B

  3/28/2023

  Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop targeted radioligand therapies in oncology.

• Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

  3/28/2023

  Bicycle Therapeutics plc today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets.

• Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  2/28/2023

  Bicycle Therapeutics plc today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent corporate updates.

• Bicycle Therapeutics to Participate in Upcoming March 2023 Investor Conferences

  2/28/2023

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in the following investor conferences in March.

• Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009

  2/14/2023

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced monotherapy Phase I dose escalation results of the ongoing Phase I/II trial of BT8009, a novel BTC™ targeting Nectin-4.